Koutaroh Okada
Overview
Explore the profile of Koutaroh Okada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shimizu Y, Okada K, Adachi J, Abe Y, Narumi R, Uchibori K, et al.
NPJ Precis Oncol
. 2022 Mar;
6(1):16.
PMID: 35301419
Anaplastic lymphoma kinase (ALK) fusion is found in ~3%-5% of patients with non-small-cell lung cancers (NSCLCs). Although the third-generation ALK tyrosine kinase inhibitor (TKI) lorlatinib shows high clinical efficacy in...
2.
Tanimura K, Yamada T, Okada K, Nakai K, Horinaka M, Katayama Y, et al.
NPJ Precis Oncol
. 2022 Jan;
6(1):5.
PMID: 35042943
Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) have shown dramatic efficacy in patients with ALK-rearranged lung cancer; however, complete response in these patients is rare. Here, we investigated the molecular mechanisms...
3.
Mizuta H, Okada K, Araki M, Adachi J, Takemoto A, Kutkowska J, et al.
Nat Commun
. 2021 Feb;
12(1):1261.
PMID: 33627640
ALK gene rearrangement was observed in 3%-5% of non-small cell lung cancer patients, and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple ALK-TKI resistance mutations have been identified...
4.
Takahashi K, Seto Y, Okada K, Uematsu S, Uchibori K, Tsukahara M, et al.
Thorac Cancer
. 2020 Jan;
11(3):581-587.
PMID: 31943796
Background: Anaplastic lymphoma kinase (ALK) fusion genes are found in 3%-5% of non-small cell lung cancers (NSCLCs). ALK inhibitors show a very high response rate to ALK-positive NSCLCs. However, the...
5.
Okada K, Araki M, Sakashita T, Ma B, Kanada R, Yanagitani N, et al.
EBioMedicine
. 2019 Jan;
41:105-119.
PMID: 30662002
Background: Alectinib has shown a greater efficacy to ALK-rearranged non-small-cell lung cancers in first-line setting; however, most patients relapse due to acquired resistance, such as secondary mutations in ALK including...
6.
Fuse M, Okada K, Oh-Hara T, Ogura H, Fujita N, Katayama R
Mol Cancer Ther
. 2017 Jul;
16(10):2130-2143.
PMID: 28751539
() gene rearrangement leads to constitutive activation of NTRK1, which induces high-transforming ability. NTRK-rearranged cancers have been identified in several cancer types, such as glioblastoma, non-small cell lung cancer, and...
7.
Perez Goodwyn P, Katsumata-Wada A, Okada K
J Insect Physiol
. 2009 Jun;
55(9):855-61.
PMID: 19523956
Substrate vibratory information receptors are extensively studied in insects and spiders, however for water surface dwelling species little data is available. We studied the vibration receptive organs in tarsi of...
8.
Okada K, Sakuma M
Chem Senses
. 2009 Apr;
34(5):425-33.
PMID: 19363088
The olfactory system of an insect brain codes for information about odorant quality and quantity using the temporal pattern of neural activity as well as neurons' firing. Although an accurate...
9.
Hill E, Okada K, Kanzaki R
J Exp Biol
. 2002 Dec;
206(Pt 2):345-52.
PMID: 12477903
A unique serotonin-immunoreactive neuron innervates every glomerulus of the contralateral antennal lobe (AL), the primary olfactory center, of the male silkmoth Bombyx mori. In order to examine the possible modulatory...